IBB stock sentiment todayiShares Biotechnology ETF
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
IBB
iShares Biotechnology ETFIBB offers stable exposure to biotech titans, but it is currently being overshadowed by high-growth AI sectors and faces pressure from impending patent cliffs.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for IBB. Not financial advice.
Price · last 12 months
Gossip
Market sentiment is currently split; while some analysts see a technical 'breakout' opportunity using long calls, others warn that capital is rotating away from biotech toward AI and Space stocks. Recent institutional interest from Old National Bancorp suggests some 'smart money' accumulation, but the broader narrative is one of a sector waiting for a clear catalyst like lower interest rates.
- ·Speculation on 2025/2026 risk-on rotation
- ·Options trading volume around the $210-220 strike price
- ·Comparison to more concentrated biotech ETFs like FBT
Financial
IBB is a market-cap-weighted ETF, meaning it is anchored by cash-rich giants like Amgen, Vertex, and Gilead. While these companies have robust balance sheets, the fund's growth is hampered by the 'patent cliff' facing major biologics and a slower M&A environment compared to historical peaks.
- ·Expense Ratio: 0.44%
- ·P/E Ratio: ~18-20x (Forward)
- ·Top 10 holdings represent ~45-50% of total weight
Risks
- ·Interest rate sensitivity (higher rates increase the cost of R&D for smaller components)
- ·Drug price negotiations under the Inflation Reduction Act
- ·Concentration risk in large-cap legacy biotech
Peer temperature
How direct competitors stack up against IBB right now.
- HOTXBISPDR S&P Biotech ETF
HOTTER — equal-weighted structure offers much higher sensitivity to M&A activity and clinical trial breakthroughs in small-cap firms.
See full analysis → - NEUTRALFBTFirst Trust NYSE Arca Biotech ETF
NEUTRAL — more concentrated and volatile than IBB, but historically delivers higher alpha during bull cycles due to its tiered weighting.
See full analysis → - COLDARKGARK Genomic Revolution ETF
COLDER — focuses on high-risk gene editing and sequencing which has significantly underperformed IBB's stable large-cap anchors.
See full analysis →
- IBB+3.4%
- XBI-1.1%
- FBT+2.3%
- ARKG-5.2%
Recent headlines
- MoomooIBB 261120 210.00C (IBB261120C210000) Stock Community & Discussion
- MarketBeatIBB Top Holdings List & Exposure (iShares Biotechnology ETF)
- The Motley FoolHow to Invest in iShares Biotechnology ETF (IBB)
- Quiver QuantitativeFund Update: New $12.8M $IBB stock position opened by OLD NATIONAL BANCORP |IN|
- Seeking AlphaIBB: Space Stocks And AI Stealing The Risk-On Show In 2026 (NASDAQ:IBB)
- CoinGeckoiShares Biotechnology ETF (IBB) Stock Price, Chart & News Today
AI-generated analysis for informational purposes only. Not financial advice.